TY - JOUR
T1 - Structure-function relationship of human parathyroid hormone in the regulation of vitamin d receptor expression in osteoblast-like cells (ROS 17/2.8)
AU - Sriussadaporn, Sutin
AU - Wong, Man Sau
AU - Whitfield, James F.
AU - Tembe, Vrishali
AU - Favus, Murray J.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Studies of the relationship between PTH structure and function in the activation of protein kinases have revealed that different regions within the biologically active PTH-(1-34) peptide are responsible for different functions. The first two N-terminal amino acids are required for plasma membrane adenylyl cyclase stimulation, and the C-terminal region 29-32 is necessary for the translocating activity of protein kinase C. In the present study, we explored the structure-function relationship of human (h) PTH in the regulation of the vitamin D receptor (VDR) in osteoblast-like cells (ROS 17/2.8). VDR-rich cytosol extract was prepared after the confluent cells were incubated with different hPTH fragments for 16 h. hPTH-(1-34) at concentrations of 10(-9)-10(-7) M caused a dose-dependent decrease in VDR content from a control level of 70.2 ± 2.2 fmol/mg protein to 62.1 ± 3.3 (-16%) at 10(-9) M, 52.3 ± 5.3 (-25.5%; P < 0.02) at 10(-8) M, and 45.5 ± 3.5 fmol/mg protein (-35.3%; P = 0.001) at 10(-7) M (n = 6). hPTH-(1-31) also decreased VDR content from 65.5 ± 3.6 to 55.2 ± 7.9 (-19.5%) at 10(-9) M, 44.3 ± 5.8 (-32.4%; P < 0.05) at 10(-8) M, and 40.6 ± 3.2 fmol/mg protein (-38.9%; P < 0.05) at 10(-7) M (n = 6). Incubation of ROS 17/2.8 cells with 0.5 nM 1, 25-dihydroxyvitamin D3 [1, 25-(OH)2D3] led to up-regulation of VDR content by 340-370% of the control value. hPTH-(1-34) decreased the VDR up-regulatory effect of 1, 25-(OH)2D3 from 340% to 230% of the control value at 10(-8) M (P < 0.0001) and 170% of the control value (P < 0.0001) at 10(-7) M, respectively (n = 6). hPTH-(1-31) also decreased the receptor up-regulatory effect of 1, 25-(OH)2D3 from 370% to 286% (P < 0.02) at 10(-8) M and 220% (P < 0.002) at 10(-7) M, respectively (n = 6). hPTH-(3-34) and -(13-34) at concentrations of 10(-9)-10(-7) M did not decrease VDR content in either the absence or presence of 1, 25-(OH)2D3. Quantitation of VDR messenger RNA by reverse transcription-polymerase chain reaction showed that PTH-(1-34) and -(1-31) at 10(-7) M, but not PTH-(3-34) and -(13-34), inhibited ROS 17/2.8 cell VDR gene expression in both the absence and presence of 1, 25-(OH)2D3.adenylyl cyclase-stimulating domain is responsible for PTH-mediated downregulation of VDR in ROS 17/2.8 cells.
AB - Studies of the relationship between PTH structure and function in the activation of protein kinases have revealed that different regions within the biologically active PTH-(1-34) peptide are responsible for different functions. The first two N-terminal amino acids are required for plasma membrane adenylyl cyclase stimulation, and the C-terminal region 29-32 is necessary for the translocating activity of protein kinase C. In the present study, we explored the structure-function relationship of human (h) PTH in the regulation of the vitamin D receptor (VDR) in osteoblast-like cells (ROS 17/2.8). VDR-rich cytosol extract was prepared after the confluent cells were incubated with different hPTH fragments for 16 h. hPTH-(1-34) at concentrations of 10(-9)-10(-7) M caused a dose-dependent decrease in VDR content from a control level of 70.2 ± 2.2 fmol/mg protein to 62.1 ± 3.3 (-16%) at 10(-9) M, 52.3 ± 5.3 (-25.5%; P < 0.02) at 10(-8) M, and 45.5 ± 3.5 fmol/mg protein (-35.3%; P = 0.001) at 10(-7) M (n = 6). hPTH-(1-31) also decreased VDR content from 65.5 ± 3.6 to 55.2 ± 7.9 (-19.5%) at 10(-9) M, 44.3 ± 5.8 (-32.4%; P < 0.05) at 10(-8) M, and 40.6 ± 3.2 fmol/mg protein (-38.9%; P < 0.05) at 10(-7) M (n = 6). Incubation of ROS 17/2.8 cells with 0.5 nM 1, 25-dihydroxyvitamin D3 [1, 25-(OH)2D3] led to up-regulation of VDR content by 340-370% of the control value. hPTH-(1-34) decreased the VDR up-regulatory effect of 1, 25-(OH)2D3 from 340% to 230% of the control value at 10(-8) M (P < 0.0001) and 170% of the control value (P < 0.0001) at 10(-7) M, respectively (n = 6). hPTH-(1-31) also decreased the receptor up-regulatory effect of 1, 25-(OH)2D3 from 370% to 286% (P < 0.02) at 10(-8) M and 220% (P < 0.002) at 10(-7) M, respectively (n = 6). hPTH-(3-34) and -(13-34) at concentrations of 10(-9)-10(-7) M did not decrease VDR content in either the absence or presence of 1, 25-(OH)2D3. Quantitation of VDR messenger RNA by reverse transcription-polymerase chain reaction showed that PTH-(1-34) and -(1-31) at 10(-7) M, but not PTH-(3-34) and -(13-34), inhibited ROS 17/2.8 cell VDR gene expression in both the absence and presence of 1, 25-(OH)2D3.adenylyl cyclase-stimulating domain is responsible for PTH-mediated downregulation of VDR in ROS 17/2.8 cells.
UR - http://www.scopus.com/inward/record.url?scp=0029150927&partnerID=8YFLogxK
U2 - 10.1210/endo.136.9.7649079
DO - 10.1210/endo.136.9.7649079
M3 - Journal article
C2 - 7649079
SN - 0013-7227
VL - 136
SP - 3735
EP - 3742
JO - Endocrinology
JF - Endocrinology
IS - 9
ER -